Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate

Kidney International

Volumn 79, Issue 2, 2011, Pages 234-240

  Pavik, Ivana ^a   Jaeger, Philippe ^b   Kistler, Andreas D ^c   Poster, Diane ^c   Krauer, Fabienne ^c   Cavelti Weder, Claudia ^c   Rentsch, Katharina M ^d   Wüthrich, Rudolf P ^a,c   Serra, Andreas L ^a,c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

autosomal dominant polycystic kidney disease; fibroblast growth factor 23; parathyroid hormone

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOPHOSPHATEMIA; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAMETER; PHOSPHATE METABOLISM; PRIORITY JOURNAL;

EID: 78650918998     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.375     Document Type: Article

References (37)

1. Grantham JJ, Torres VE, Chapman AB et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-2130.
2. Kistler AD, Poster D, Krauer F et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 2009; 75: 235-241.
3. Poster D, Kistler AD, Krauer F et al. Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case series. Am J Kidney Dis 2009; 54: 450-458.
4. Wong H, Vivian L, Weiler G et al. Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. Am J Kidney Dis 2004; 43: 624-628.
5. Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. Am Soc Clin Invest 2003;112: 642-646.
6. Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Ann Rev Physiol 2007; 69: 341-359.
7. Consortium A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26: 345-348.
8. Francis F, Hennig S, Korn B et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet1995;11:130-136.
9. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505.
10. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007;18:1637-1647.
11. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16: 2205-2215.
12. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18: 2600-2608.
13. Ix JH, Shlipak MG, Wassel CL et al. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010; 25: 993-997.
14. Evenepoel P, Meijers B, Viaene L et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010.
15. Westerberg PA, Linde T, Wikstrom B et al. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3202-3207.
16. van Husen M, Fischer AK, Lehnhardt A et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 2010.
17. Manghat P, Fraser WD, Wierzbicki AS et al. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 2009.
18. Mirams M, Robinson BG, Mason RS et al. Bone as a source of FGF23: regulation by phosphate? Bone 2004; 35:1192-1199.
19. Imel EA, Peacock M, Pitukcheewanont P et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006; 91: 2055-2061.
20. Ferrari SL, Bonjour J-P, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90:1519-1524.
21. Isakova T, Gutierrez O, Shah A et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008;19: 615-623.
22. Driscoll JA, Bhalla S, Liapis H et al. Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis. Chest 2008;133:1181-1188.
23. Gunay-Aygun M. Liver and kidney disease in ciliopathies. Am J Med Genet C Semin Med Genet 2009;151C: 296-306.
24. van Dijk MA, Chang PC, Peters DJ et al. Intracranial aneurysms in polycystic kidney disease linked to chromosome 4. J Am Soc Nephrol1995; 6:1670-1673.
25. Xiao Z, Zhang S, Mahlios J et al. Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression. In J Biol Chem 2006; 281: 30884-30895.
26. Boulter C, Mulroy S, Webb S et al. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci USA 2001; 98:12174-12179.
27. Hou B, Kolpakova-Hart E, Fukai N et al. The polycystic kidney disease1 (Pkd1) gene is required for the responses of osteochondroprogenitor cells to midpalatal suture expansion in mice. Bone 2009; 44:1121-1133.
28. Kolpakova-Hart E, McBratney-Owen B, Hou B et al. Growth of cranial synchondroses and sutures requires polycystin-1. Dev Biol 2008; 321: 407-419.
29. Lu W, Shen X, Pavlova A et al. Comparison of Pkd1-targeted mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects. Hum Mol Genet 2001;10: 2385-2396.
30. Xiao Z, Zhang S, Magenheimer BS et al. Polycystin-1 regulates skeletogenesis through stimulation of the osteoblast-specific transcription factor RUNX2-II. J Biol Chem 2008; 283:12624-12634.
31. Xiao Z, Zhang S, Cao L et al. Conditional disruption of Pkd1 in osteoblasts results in osteopenia due to direct impairment of bone formation. J Biol Chem 2010; 285:1177-1187.
32. Serra AL, Kistler AD, Poster D et al. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol 2007; 8:13.
33. Ravine D, Gibson RN, Walker RG et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease1. Lancet1994; 343: 824-827.
34. Bakker J, Olree M, Kaatee R et al. Renal volume measurements: accuracy and repeatability of US compared with that of MR imaging. Radiology1999; 211: 623-628.
35. Brodehl J, Krause A, Hoyer PF. Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol1988; 2:183-189.
36. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150: 604-612.
37. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl1): S1-266.